Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are no longer in shortage, the U.S. Food and Drug ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Mounjaro has been on the FDA's shortage list since late 2022, while Zepbound was added to the list in April this year.